Within 24 hours, CILS can go into production with 1,000 to hundreds of thousands of durable labels to identify patient information for COVID-19 testing
Mislabeling may lead to adverse effects for patients, including children with epilepsy
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.